62 related articles for article (PubMed ID: 38524651)
1. Consolidated BRCA1/2 Variant Interpretation by MH BRCA Correlates with Predicted PARP Inhibitor Efficacy Association by MH Guide.
Hirotsu Y; Schmidt-Edelkraut U; Nakagomi H; Sakamoto I; Hartenfeller M; Narang R; Soldatos TG; Kaduthanam S; Wang X; Hettich S; Brock S; Jackson DB; Omata M
Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32486089
[No Abstract] [Full Text] [Related]
2. Rapid Progression of Metastatic Pancreatic Adenocarcinoma During Platinum-Based Therapy in a Patient Harboring a Pathogenic BRCA2 Germline Variant.
Sorscher S; Ramkissoon S
Oncologist; 2021 Nov; 26(11):916-918. PubMed ID: 34309133
[TBL] [Abstract][Full Text] [Related]
3. Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial.
Rodler E; Sharma P; Barlow WE; Gralow JR; Puhalla SL; Anders CK; Goldstein L; Tripathy D; Brown-Glaberman UA; Huynh TT; Szyarto CS; Godwin AK; Pathak HB; Swisher EM; Radke MR; Timms KM; Lew DL; Miao J; Pusztai L; Hayes DF; Hortobagyi GN
Lancet Oncol; 2023 Feb; 24(2):162-174. PubMed ID: 36623515
[TBL] [Abstract][Full Text] [Related]
4. Case report: Response to platinum agents and poly (adenosine diphosphate-ribose) polymerase inhibitor in a patient with BRCA1 c.5096G>A (R1699Q) intermediate-risk variant.
Saito A; Tanioka M; Hirata M; Watanabe T; Odaka Y; Shimoi T; Sudo K; Noguchi E; Ishikawa M; Yonemori K
Cancer Treat Res Commun; 2022; 32():100587. PubMed ID: 35696850
[TBL] [Abstract][Full Text] [Related]
5. A case of hereditary breast and ovarian cancer syndrome of initially presented as cancer of unknown primary with lymph node metastases unveiled by genetic analysis.
Yamada J; Fukuda K; Sugawara T; Makino K; Shimazu K; Yoshida T; Taguchi D; Shinozaki H; Terada Y; Nanjo H; Shibata H
Int Cancer Conf J; 2024 Apr; 13(2):139-143. PubMed ID: 38524651
[TBL] [Abstract][Full Text] [Related]
6. Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment.
Papa A; Caruso D; Strudel M; Tomao S; Tomao F
J Transl Med; 2016 Sep; 14():267. PubMed ID: 27634150
[TBL] [Abstract][Full Text] [Related]
7. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
Parkes EE; Kennedy RD
Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
[TBL] [Abstract][Full Text] [Related]
8. Hereditary breast and ovarian cancer: from genes to molecular targeted therapies.
Ponti G; De Angelis C; Ponti R; Pongetti L; Losi L; Sticchi A; Tomasi A; Ozben T
Crit Rev Clin Lab Sci; 2023 Dec; 60(8):640-650. PubMed ID: 37455374
[TBL] [Abstract][Full Text] [Related]
9. Precision medicine for hereditary tumors in gynecologic malignancies.
Sekine M; Enomoto T
J Obstet Gynaecol Res; 2021 Aug; 47(8):2597-2606. PubMed ID: 34036697
[TBL] [Abstract][Full Text] [Related]
10. Genetic Basis of Breast and Ovarian Cancer: Approaches and Lessons Learnt from Three Decades of Inherited Predisposition Testing.
Barili V; Ambrosini E; Bortesi B; Minari R; De Sensi E; Cannizzaro IR; Taiani A; Michiara M; Sikokis A; Boggiani D; Tommasi C; Serra O; Bonatti F; Adorni A; Luberto A; Caggiati P; Martorana D; Uliana V; Percesepe A; Musolino A; Pellegrino B
Genes (Basel); 2024 Feb; 15(2):. PubMed ID: 38397209
[TBL] [Abstract][Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
